Identifying multiple myeloma patients using data from the French health insurance databases

Palmaro, Aurore; Gauthier, Martin; Conte, Cécile; Grosclaude, Pascale; Despas, Fabien; Lapeyre‐Mestre, Maryse

doi:10.1097/md.0000000000006189

Cited by 20 publications

(18 citation statements)

References 27 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…European registries found that CML annual incidence is around 1.1/100 000 , but worldwide data show many differences between countries: from 0.4/100 000 in some non‐Western countries to 1.75/100 000 in the USA . When considering CML LTD only, we identified only 50 patients, corresponding to an annual crude incidence of 0.69/100 000; this is significantly lower than incidence rates reported in cancer registries, and we could not base our selection upon such a method; however, these data are consistent with the already reported low declaration rate of LTD hematologic malignancies (around 50%) . LTD is inconstantly declared in France and of 690 patients with at least one CML TKI dispensing in our study, 91 had no LTD at all, and 137 had no cancer LTD. Thirty‐four patients have been excluded because they had CML code at least 9 months prior to F‐TKI; they must have been prevalent CML patients exiting a clinical trial (TKI having been previously refunded by the pharmaceutical firm), having had a sustained response without treatment, having moved to Midi‐Pyrénées, or having changed their insurance system while being treated by TKI.…”

Section: Discussionsupporting

confidence: 58%

Psychotropic drug initiation in patients diagnosed with chronic myeloid leukemia: a population‐based study in France

Gauthier

Conte

Palmaro

et al. 2020

Fundamemntal Clinical Pharma

Self Cite

View full text Add to dashboard Cite

Psychotropic drugs (PD) are often used close to a cancer diagnosis and may be considered as a way of coping. We aimed to determine the incidence of anxiolytics, hypnotics, antidepressants, and antipsychotics initiation around a diagnosis of chronic myelogenous leukemia (CML). Population‐based cohort: Data were extracted from Systeme National des données de Santé (SNDS, the French health insurance database) at the regional level (Midi‐Pyrenees area, 2.9 million inhabitants). All newly diagnosed patients treated by a CML tyrosine kinase inhibitor (TKI) between 10/01/2011 and 04/01/2014 were included. Pre‐CML (9 months before to 3 months before first TKI prescription—F‐TKI) and CML (3 months before to 9 months after F‐TKI) phases were defined. The main evaluation criterion was the initiation of PD during CML phase. Determinants associated with this incident PD use were studied through a logistic regression model. We compared pre‐CML and CML healthcare consumption. The cohort included 103 patients (mean age of 60.8 years). PD initiation rate was 35.9%, anxiolytics being the most initiated PD (59.5%). Advanced age was associated with PD initiation (adjusted OR = 1.029, 95% CI = 1.001–1.056). The number of consultations during the pre‐CML phase and female gender tended to be associated with increased risk of PD initiation in univariate analysis. For PD initiators, healthcare consumption was greater in CML but not in pre‐CML phase. PD initiation is a frequent finding around a CML diagnosis. Its risk increases with age. It could be a way to identify a subgroup with higher healthcare consumption.

show abstract

Section: Discussionsupporting

confidence: 58%

Psychotropic drug initiation in patients diagnosed with chronic myeloid leukemia: a population‐based study in France

Gauthier

Conte

Palmaro

et al. 2020

Fundamemntal Clinical Pharma

Self Cite

View full text Add to dashboard Cite

show abstract

“…Multiple myeloma patients were identified through hospital diagnosis or long‐term conditions, using ICD10 code for multiple myeloma (C90). The validity of this algorithm has been demonstrated elsewhere, with a sensitivity of 90%, a specificity of 100% (positive predictive value 60%, negative predictive value 100%) …”

Section: Methodsmentioning

confidence: 99%

“…The validity of this algorithm has been demonstrated elsewhere, with a sensitivity of 90%, a specificity of 100% (positive predictive value 60%, negative predictive value 100%). 11 Those with at least 1 dispensing record for lenalidomide, thalidomide, bortezomib, melphalan, doxorubicin, cyclophosphamide or bendamustine were selected.…”

Section: Patients Selectionmentioning

confidence: 99%

Identifying cancer drug regimens in French health insurance database: An application in multiple myeloma patients

Palmaro

Gauthier

Despas

et al. 2017

Pharmacoepidemiology and Drug

Self Cite

View full text Add to dashboard Cite

show abstract

“…Conversely we did not have the means to determine those patients with myeloma and for whom this information was not present in the database. A recent publication by Palmaro et al suggests that the diagnostic codes present in the PMSI database can be used with a good specificity to identify incident cases of myeloma [ 9 ].…”

Section: Methodsmentioning

confidence: 99%

Real life management of patients hospitalized with multiple myeloma in France

et al. 2018

View full text Add to dashboard Cite

BackgroundPatients with multiple myeloma included in prospective clinical trials are highly selected and therefore are expected not to be representative of the entire patient population. Additionally recommendations based on literature data and randomized trials are not systematically implemented in all patients. We sought to determine how patients hospitalized with a diagnosis of multiple myeloma are currently treated in France.Methods and findingsWe performed a nation-wide search using the Programme de Médicalisation des Systèmes d’Information (PMSI) database which includes anonymous data for all patients hospitalized in France. We identified newly diagnosed cases in 2012 and analyzed the number and duration of hospital stays, coexisting conditions and treatment modalities with data available until the end of 2015. A diagnosis of multiple myeloma was determined for the first time during a hospitalization in France in 2012 in 6,282 patients (3,234 males and 3,048 females). The median age at diagnosis was 74 years (72 in males and 76 in females). A majority (55.3%) of patients were diagnosed and treated in a single heath center, including 37% in a university hospital and 52% in a non-university public hospital. Comorbidities potentially impacting on myeloma treatment were present in 57.5% of patients at diagnosis, and 15% had an associated diagnosis of another neoplasia. Intensive therapies with stem cell transplants were performed in 1033 patients (16% of total), the majority of which were aged less than 65 (881 patients, 85.3%). Stem cell transplants were performed more frequently in males while the distance between the site of residence and the transplant center had no impact on likelihood of receiving a transplant. Only 60% of patients less than 65 years old who were treated for their disease underwent intensification with stem cell transplant within the 4-year follow-up period.ConclusionsA large majority of patients hospitalized with a diagnosis of multiple myeloma are elderly, in particular females, and not eligible for transplants. Among the patients aged less than 65 and receiving therapy for their disease, 40% do not undergo transplants. These data emphasize the need for alternative therapies.

show abstract

Identifying multiple myeloma patients using data from the French health insurance databases

Abstract: Supplemental Digital Content is available in the text

Cited by 20 publications

References 27 publications

Psychotropic drug initiation in patients diagnosed with chronic myeloid leukemia: a population‐based study in France

Psychotropic drug initiation in patients diagnosed with chronic myeloid leukemia: a population‐based study in France

Identifying cancer drug regimens in French health insurance database: An application in multiple myeloma patients

Real life management of patients hospitalized with multiple myeloma in France

Contact Info

Product

Resources

About